Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7996 to 8010 of 8939 results

  1. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    Discontinued Reference number: GID-TA11044

    Technology appraisal guidance
    Discontinued

  2. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    Discontinued Reference number: GID-TA11344

    Technology appraisal guidance
    Discontinued

  3. Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]

    Discontinued Reference number: GID-TA11467

    Technology appraisal guidance
    Discontinued

  4. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    Discontinued Reference number: GID-TA11569

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    Discontinued Reference number: GID-TA11401

    Technology appraisal guidance
    Discontinued

  6. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development Reference number: GID-TA10555 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]

    Discontinued Reference number: GID-TA10567

    Technology appraisal guidance
    Discontinued

  8. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

    Discontinued Reference number: GID-TA10569

    Technology appraisal guidance
    Discontinued

  9. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued Reference number: GID-TA10570

    Technology appraisal guidance
    Discontinued

  10. Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

    Discontinued Reference number: GID-TA10574

    Technology appraisal guidance
    Discontinued

  11. Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

    In development Reference number: GID-TA10577 Expected publication date:  21 April 2021

    Technology appraisal guidance
    In development

  12. Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

    Discontinued Reference number: GID-TA10585

    Technology appraisal guidance
    Discontinued

  13. Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

    In development Reference number: GID-TA10589 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

    Discontinued Reference number: GID-TA10590

    Technology appraisal guidance
    Discontinued

  15. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued Reference number: GID-TA10591

    Technology appraisal guidance
    Discontinued